Gastrointestinal (GI) cancers ectopically express multiple splice variants of the cholecystokinin-2 (CCK 2 )/gastrin receptor; however, their relative contributions to the cancer phenotype are unknown. The aim of this study was to compare the effects of CCK 2 receptor (CCK 2 R) and CCK 2i4sv R expression on cell growth both in vitro and in vivo using a human epithelial cell model, HEK239. In vitro, receptor variant expression did not affect cell proliferation either in the absence or presence of agonist. However, in vivo, the expression of CCK 2i4sv R, but not CCK 2 R, increases HEK293 tumor growth in a constitutive, Src-dependent manner. Enhanced tumorigenicity of CCK 2i4sv R is associated with an Src-dependent increase in the transcription factor, hypoxia-inducible factor-1a, its downstream target, vascular endothelial growth factor and tumor micro-vessel density, suggesting that CCK 2i4sv R may contribute to the growth and spread of GI cancers through agonist-independent mechanisms that enhance tumor angiogenesis.
Introduction
The peptide hormone gastrin and its biosynthetic precursors stimulate gastrointestinal (GI) cancer cell growth, migration (Noble et al., 2003) and invasion (Wroblewski et al., 2002) . The actions of gastrin are mediated by the cholecystokinin-2 (CCK 2 )/gastrin receptor, a member of the G protein-coupled receptor superfamily. Human GI cancers ectopically express at least three splice variants of the CCK 2 receptor (CCK 2 R) gene: (1) CCK 2 R, the original variant identified as the receptor mediating normal gastric acid secretion and enterochromaffin-like cell (enhanced chemiluminescence (ECL)) proliferation (Dockray et al., 2005) in mammals, (2) an N-terminal truncated form of CCK 2 R (DCCK 2 R) (Miyake, 1995) and (3) CCK 2i4sv R, which owing to intron 4 retention, contains an additional 69 amino-acid residues in its third intracellular loop domain (Hellmich et al., 2000) . DCCK 2 R is expressed in colorectal and gastric cancerderived cell lines (McWilliams et al., 1998; Smith and Watson, 2000) . CCK 2 R is ectopically expressed in colorectal carcinomas (Schmitz et al., 2001) , metaplastic cells associated with Barrett's esophagus (Harris et al., 2004) and esophageal adenocarcinomas (Moore et al., 2004) . It is overexpressed in pancreatic (Guo and Townsend, 2000) and gastric cancers (Iwase et al., 1997) . Similar to CCK 2 R, CCK 2i4sv R is also expressed in colorectal cancers and premalignant polyps (Hellmich et al., 2000) , human pancreatic cancers and cancerderived cell lines (Ding et al., 2002; Smith et al., 2002) , and Barrett's metaplasia (Harris et al., 2004) .
To date, no significant functional differences between CCK 2 R and DCCK 2 R have been documented. However, several important differences between CCK 2 R and CCK 2i4sv R have been noted in cell culture models. We have previously reported that CCK 2i4sv R exhibits agonist-independent (constitutive) activation of the protooncogene Src kinase, and Harris et al. (2004) have reported constitutive activation of Akt in an esophageal cancer cell line. Additionally, we have shown that CCK 2i4sv R resensitizes to repeated agonist stimulation significantly faster than CCK 2 R (Chao et al., 2005) . The rapid resensitization rate of CCK 2i4sv R is a consequence of its Src-dependent, constitutive internalization, which creates an intracellular pool of receptors that rapidly recycles back to the plasma membrane.
These in vitro differences, coupled with the fact that both CCK 2 R and CCK 2i4sv R are expressed in the same cancers, suggest that each receptor variant may contribute to the cancer phenotype in a differential manner. However, a direct comparison of CCK 2 R and CCK 2i4sv R in the same cell background has not been performed. The aim of this study was to compare the effects of CCK 2 R and CCK 2i4sv R expression on cell growth both in vitro and in vivo using a human epithelial cell model, HEK293. We report that, in contrast to CCK 2 R, the expression of CCK 2i4sv R stimulates HEK293 tumor growth in an agonist-independent, Src-dependent manner. Additionally, we show that the enhanced tumorigenicity of CCK 2i4sv R is associated with Src-dependent upregulation of the transcription factor, hypoxia-inducible factor (HIF)-1a, its downstream target, vascular endothelial growth factor (VEGF) and increased tumor angiogenesis.
Results
Receptor variant expression affects the rate of HEK293 cell growth in vivo but not in vitro Although CCK 2 R and CCK 2i4sv R are aberrantly expressed in premalignant lesions and carcinomas of the esophagus, pancreas and colorectum, their relative roles in tumor progression remains largely undefined. To determine their potential role in regulating epithelial tumor cell growth, we compared expression of CCK 2i4sv R and CCK 2 R in HEK293 cells in vitro and in vivo using a mouse xenograft model. Table 1 summarizes the results of in vitro growth assays. The growth rates in the presence and absence of 10 nM gastrin1-17 (G17) for four receptor-expressing clonal lines -two expressing CCK 2 R and two expressing CCK 2i4sv R -were compared. Although the level of receptor expression varied between the lines, no significant differences were noted in their doubling times either in the absence (Table 1 , analysis of variance (ANOVA), P ¼ 0.39) or presence of 10 nM G17 (data not shown). Distinct from the in vitro results, when implanted subcutaneously in nu/nu Balb C mice, cells expressing CCK 2i4sv R grew significantly faster and produced larger tumors when compared to cells expressing CCK 2 R, the empty expression vector (Figure 1a) , or the parental HEK293 cell line (data not shown). Figure 1b is a series of photographs of representative tumors from each group harvested on day 22.
Constitutive CCK 2i4sv R activity increases HEK293 tumor growth As gastrin and its biosynthetic precursor, non-amidated glycine-extended gastrin, both have the ability to stimulate the growth of GI cancers in rodents and humans (McGregor et al., 1982; Sirinek et al., 1985; Winsett et al., 1986; Smith and Solomon, 1988; Watson et al., 1989; Smith et al., 1995; Smith et al., 1998; Harris et al., 2004) , we assessed whether the increased tumor growth rate associated with CCK 2i4sv R expression was due to receptor activation by endogenous gastrin. Mice were injected with cells stably transfected with CCK 2i4sv R or CCK 2 R. After 2 days, they were randomly separated into four groups for each receptor variant, and treated either with saline, the CCK 2 R selective antagonist (CR2945), the CCK 2 R agonist (pentagastrin), or a combination of CR2945 and pentagastrin. Both CR2945 and pentagastrin were delivered at a dose of 30 mg/kg daily. The affinity of CR2945 for the CCK 2 R variants is approximately 100-fold higher than that of pentagastrin. At the end of week 3, tumor tissues were harvested and weighed. Comparison of the saline-treated groups showed that CCK 2i4sv R-expressing tumors, at the time of harvest, weighed approximately 12.5-fold more than those Figure 2 ). Combined treatment with CR2945 and pentagastrin blocked the stimulatory effects of agonist, confirming the antagonist function of CR2945. Together, these data indicate that the increased basal rate of tumor growth associated with CCK 2i4sv R expression is not due to receptor activation by endogenous gastrin, but rather, involves an agonistindependent mechanism.
Expression of dominant-negative Src inhibits CCK 2i4sv R-induced HEK293 tumor growth Previously, we reported that CCK 2i4sv R constitutively activates the protooncogene Src kinase in HEK293 cells (Olszewska-Pazdrak et al., 2004) . To determine the role of CCK 2i4sv R-regulated Src activity in tumor growth, receptor-expressing cells were infected in vitro with a retroviral expression construct containing either the empty viral vector or a kinase-dead Src mutant (A430V) that functions as a dominant-negative (dn) (Ishizawar et al., 2004) . Staining of the cells for b-galactosidase confirmed greater than 99% retroviral infection efficiency. Coexpression of dnSrc with either CCK 2 R or CCK 2i4sv R did not affect the growth rate of cells in culture ( Figure 3a) . However, expression of dnSrc with CCK 2i4sv R significantly slowed the rate of tumor growth in vivo (Figure 3b ) and decreased tumor weight by 66% at harvest (Figure 3c ). The inhibitory effect of dnSrc expression on growth rate was most pronounced between days 10 and 15 post-injection ( Figure 3a) . After day 15, the rate of tumor growth began to increase to a rate that was equivalent to CCK 2i4sv R-expressing tumor infected with empty viral vector at harvest (Figure 3a) . Coexpression of dnSrc did not significantly affect the growth of either CCK 2 R-expressing tumors (Figure 3) or the parental HEK293 cell line (data not shown). These data demonstrate that the increased basal growth rate in vivo of CCK 2i4sv R-expressing HEK293 cells is due, in part, to Src kinase. CCK 2i4sv R expression stimulated an Src-dependent increase in HIF-1a protein levels Src may stimulate tumor growth by increasing the expression of the tumor-promoting factor, HIF-1a (Karni et al., 2002) . HIF-1 regulates genes involved in cell survival, glucose metabolism and angiogenesis (Semenza, 2003) . HIF-1a protein levels were determined by Western blot using 80-90% confluent cultures of receptor-expressing cells grown under normoxia (Figure 4a ). The basal level of HIF-1a protein was significantly elevated in CCK 2i4sv R-expressing cells (approximately twofold, range: 1.5-to 2.6-fold, n ¼ 9, Po0.001) relative to the CCK 2 R-expressing cells (Figure 4a ). Coexpression of dnSrc decreased CCK 2i4sv R-induced HIF-1a expression by a level similar to cells expressing CCK 2 R ( Figure 4B ), supporting the conclusion that constitutive CCK 2i4sv R-mediated Src activation leads to increased basal levels of HIF-1a protein.
Increased HIF-1a expression is associated with increased steady-state levels of VEGF mRNA expression, VEGF secretion and tumor micro-vessel density HIF-1a heterodimerizes with HIF-1b to form a basic helix-loop-helix transcription factor that regulates the expression of multiple downstream target genes, including the gene encoding VEGF (Choi et al., 2003) . To assess the effects of HIF-1a protein expression on steady-state levels of VEGF mRNA, Northern blot analyses were performed using total RNA isolated from both CCK 2i4sv R-and CCK 2 R-expressing cells cultured under normoxic conditions. CCK 2i4sv R-expressing cells exhibited a twofold higher level of VEGF mRNA when compared to CCK 2 R cells (Figure 5a ). The increase in VEGF mRNA expression was associated with an approximately fivefold increase in VEGF secretion by CCK 2i4sv R-expressing cells in culture (Figure 5b) , and an approximately twofold increase in the micro-vessel density (MVD) of CCK 2i4sv R tumors ( Figure 6 ). Together, these data suggest that the elevated level of HIF-1a protein associated with CCK 2i4sv R expression results in an increase in HIF-1-mediated transcription of VEGF and enhanced tumor angiogenesis.
Discussion
GI cancers aberrantly express several variants of the CCK 2 R (Hellmich et al., 2000; Smith and Watson, 2000; Smith et al., 2002; Aly et al., 2004) . In this study, we have compared the growth-promoting potential both CCK 2i4sv R stimulates Src-dependent tumor growth C Chao et al in vitro and in vivo of two variants: CCK 2 R and CCK 2i4sv R. In cell culture, we did not observe a difference in the basal growth rates between cells expressing either receptor variant, nor did gastrin treatment enhance their proliferation. In contrast, HEK293 cells expressing CCK 2i4sv R grew robustly in vivo, compared to CCK 2 R-expressing cells or cells transfected with the empty expression vector. Furthermore, the increased growth rate associated with the CCK 2i4sv R expression was due to constitutive receptor activity, and not the result of endogenous gastrin, as the CCK 2 R antagonist CR2945 failed to inhibit the basal CCK 2i4sv R-induced growth (Figure 2) . Previously, we and others have reported that the CCK 2i4sv R exhibits constitutive activity (Harris et al., 2004; Chao et al., 2005) , including a twofold higher level of basal Src kinase activation (1.970.2 for CCK 2i4sv R vs 1.170.1 for CCK 2 R) in the HEK293 cell model (Olszewska-Pazdrak et al., 2004) . Here, we show that coexpression of dnSrc (kinase-dead mutant) inhibited the increased basal growth rate of CCK 2i4sv R-expressing tumors in vivo. Src kinase activity is elevated in human esophageal (Kumble et al., 1997) , pancreatic (Lutz et al., 1998) and colorectal adenocarcinomas (Talamonti et al., 1993; Iravani et al., 1998) , which express CCK 2i4sv R. In these cancers, Src activity is associated with tumor growth, invasion, metastasis and angiogenesis (Weber et al., 1992; Cartwright et al., 1994) . One mechanism by which Src can regulate these processes is by the modulation of HIF-1a expression. Src increases HIF-1a protein levels by enhancing cap-dependent translation (Karni et al., 2002) , which in turn leads to HIF-1-dependent transcription of genes such as VEGF (Semenza, 2003) . CCK 2i4sv R-HEK293 cells constitutively express approximately twofold more HIF-1a than the CCK 2 R-HEK293 cells, which was markedly attenuated by coexpression of dnSrc. As the inhibitory effect of dnSrc on the growth rate of CCK 2i4sv Rexpressing tumors was most pronounced during the first 2 weeks of the experiments, the data suggest that the Src-dependent increase in basal HIF-1a protein confers a significant initial growth advantage in vivo, which may result from VEGF-induced angiogenesis. This conclusion is supported, in part, by the observation that CCK 2i4sv R-expressing tumors show an approximately twofold increase in MVD when compared to tumors expressing CCK 2 R. Future studies will further test the validity of this proposed mechanism.
Epidemiological evidence indicates that hypergastrinemia represents a minimal risk (8.6%) for developing colorectal cancer (Thorburn et al., 1998) . Furthermore, the role of the CCK 2 R variants in mediating the oncogenic actions of gastrin and its biosynthetic precursors on GI cancers remains controversial (Aly et al., 2004) . The present study contributes to the growing body of experimental evidence, supporting the hypothesis that CCK 2i4sv R may enhance the growth and spread of GI cancers through agonist-independent mechanisms.
Materials and methods
Plasmid expression constructs and transfected cell lines CCK 2 R and CCK 2i4sv R expression plasmids were constructed as described previously (Olszewska-Pazdrak et al., 2004) . HEK293 cells were transfected with receptor constructs using Lipofectamine Plus Reagent (Gibco BRL, Gaithersburg, MD, USA) and selected using G418 (800 mg/ml). The level of receptor expression for each clonal line was quantified using labeled agonist binding to isolated cell membranes . To control for possible clonal variation, two clonal lines for each receptor variant were used in all experiments. All cells were routinely cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS) and G418 (400 mg/ml) at 371C in a humidified 95% air, 5% CO 2 atmosphere.
Retroviral expression construct
The dnSrc (A430V) cDNA was cloned into a bicistronic packaging murine retroviral vector based on pFB (Stratagene, Cedar Creek, TX, USA) using SalI and EcoRI sites. The vector contains the murine leukemia retrovirus packaging sequence and a multiple cloning site, flanked by the murine leukemia virus (MLV) long terminal repeat (LTR) regions. The 5 0 LTR functions as a strong promoter upon chromosomal integration of proviral DNA. The pFB plasmid was modified to contain a cassette comprising an encephalomyocarditis virus (ECMV) internal ribosome entry site followed by a gene encoding b-galactosidase (modified with a nuclear localization signal), which enabled retrovirus titer and transcript expression levels to be determined by staining for b-galactosidase . Retroviruses were made by simultaneous transfection of HEK293FT cells (Invitrogen, Carlsbad, CA, USA) with the dnSrc expression plasmid and plasmids encoding MLV gag-pol and vesicular stomatitis virus envelope protein. Cell supernatants were collected and filtered through a 0.45 mm filter to remove cell debris before infection.
In vitro growth assay To study the effects of receptor variant expression on HEK293 cell growth in vitro, single-cell suspensions of 2 Â 10 4 cells were seeded into 24-well plates in triplicate and cultured in 1.0 ml DMEM supplemented with 1% FBS with or without 10 nM G17. Cells were trypsinized and counted by a Coulter counter daily for 8 days. The doubling time was calculated using the GraphPad Prism program, version 4.0 (GraphPad Software Inc., San Diego, CA, USA).
In vivo tumorigenesis assay The athymic nude mouse xenograft model was used to assess the effects of receptor variant expression on HEK293 cell growth in vivo. The epithelial cell line, HEK293, has been transformed by adenovirus, but is poorly tumorigenic in nude mice (Graham et al., 1977) . Replicates (n ¼ 5-9 mice per group) of nu/nu BalbC female mice (age 8-10 weeks, weight approximately 20 g each) were injected subcutaneously with 4 Â 10 6 cells per clonal cell line in the left dorsum. Tumor diameters were measured transcutaneously using calipers over a 3-week period. Tumor volumes for the generally spherical tumors were calculated using the formula: volume ¼ 4/3pr 3 . On day 22, tumors were harvested and weighed. To analyze the change in tumor diameter, ANOVA (SAS, Release 9.1) for two factors with repeated measures on time was used. The two factors were receptor group (CCK 2 R vs CCK 2i4sv R) and time (day). All effects and interactions were assessed at 0.05 level of significance. All experiments were repeated two to four times.
Western blot
Cells were plated into 12 wells at a density of approximately 10 5 cells/well in DMEM supplemented with 10% FBS. After 2 days, cells were washed with ice-cold phosphate-buffered saline and solubilized in lysis buffer containing 1% Triton X-100, 150 mM NaCl, 20 mM Tris (pH 7.5), 1 mM ethyleneglycoltetraacetate, 1 mM ethylenediaminetetraacetic acid, 2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate, 1 mM Na 3 VO 4 , 1mM phenylmethylsulfonyl fluoride and 5 mg/ml each of chymostatin, pepstatin A, leupeptin and antipain at 41C for 15 min. Triton X-100 insoluble cellular material was removed by centrifugation at 14 000 r.p.m. for 15 min, and the protein concentrations of the supernatant were determined using the Bio-Rad DC protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA). Protein (10-20 mg) from each sample was resolved on 8% sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis, transferred to nitrocellulose membrane and probed with anti-HIF-1a antibody (BD Bioscience, Franklin Lakes, NJ, USA). Immunoreactive proteins were visualized using the ECL Western blotting detection system (Amersham Biosciences, Piscataway, NY, USA). The blots were stripped and re-probed for b-actin (Santa Cruz Biotechnologies, Santa Cruz, CA, USA) to insure the equal protein loading in all lanes.
Northern blot analysis Total RNA was isolated from cells using Ultraspec reagent (Biotecx, Houston, TX, USA). For Northern blot hybridization, 10 mg of total RNA was resolved on 1% agarose/ formaldehyde gels by electrophoresis and transferred to Hybond-N þ membrane (Amersham Pharmacia Biotech, Buckinghamshire, UK). Membranes were probed with VEGF cDNA labeled with [a-32 P]-dATP (Perkin-Elmer Life Sciences Inc., Boston, MA, USA) using a random-priming DNAlabeling kit (Stratagene, Cedar Creek, TX, USA). Prehybridization (30 min) and hybridization (3 h) were performed at 681C in Express Hybridization Solution (Clontech, Palo Alto, CA, USA). Following hybridization, the blots were washed for the final time at high stringency in a solution containing 0.1 Â SSC and 0.1% SDS for 30 min at 651C. Specific hybridization was visualized by autoradiography using Bio-Max MR film (Kodak, Rochester, NY, USA). To ensure RNA integrity and to confirm equal loading of lanes and transfer of RNA during blotting, the membranes were stripped and hybridized with a probe for 18S ribosomal RNA.
Immunohistochemistry
Before immunostaining, frozen tumor sections (7 mm thick) were fixed at À201C for 2 min in acetone, treated with 0.3% H 2 O 2 (two times, 10 min), and blocked with 1% goat serum for 30 min at room temperature (RT). The tumor sections were then incubated with purified rat anti-mouse CD31 monoclonal antibody (BD Pharmingen, San Diego, CA, USA) (1:50 dilution) for 90 min at RT, followed by an incubation with a biotinylated goat polyclonal anti-rat immunoglobulin G (1:50 dilution) and streptravidin-horseradish peroxidase for 30 min at RT. Specific staining was visualized after treatment with diaminobenzidine for 7 min at RT. MVD was determined by counting the number of CD31-positive vessels per 40 Â field by two independent observers. Data were collected from three non-overlapping fields for each section; two to three sections were analysed per tumor, and four to five tumors per group (CCK 2isv R vs CCK 2 R) were examined.
